Literature DB >> 10754298

Fractalkine-mediated endothelial cell injury by NK cells.

O Yoneda1, T Imai, S Goda, H Inoue, A Yamauchi, T Okazaki, H Imai, O Yoshie, E T Bloom, N Domae, H Umehara.   

Abstract

Endothelial cells (ECs) are primary targets of immunological attack, and their injury can lead to vasculopathy and organ dysfunction in vascular leak syndrome and in rejection of allografts or xenografts. A newly identified CX3C-chemokine, fractalkine, expressed on activated ECs plays an important role in leukocyte adhesion and migration. In this study we examined the functional roles of fractalkine on NK cell activity and NK cell-mediated endothelial cell injury. Freshly separated NK cells expressed the fractalkine receptor (CX3CR1) determined by FACS analysis and efficiently adhered to immobilized full-length fractalkine, but not to the truncated forms of the chemokine domain or mucin domain, suggesting that fractalkine functions as an adhesion molecule on the interaction between NK cells and ECs. Soluble fractalkine enhanced NK cell cytolytic activity against K562 target cells in a dose- and time-dependent manner. This enhancement correlated well with increased granular exocytosis from NK cells, which was completely inhibited by the G protein inhibitor, pertussis toxin. Transfection of fractalkine cDNA into ECV304 cells or HUVECs resulted in increased adhesion of NK cells and susceptibility to NK cell-mediated cytolysis compared with control transfection. Moreover, both enhanced adhesion and susceptibility of fractalkine-transfected cells were markedly suppressed by soluble fractalkine or anti-CX3CR1 Ab. Our results suggest that fractalkine plays an important role not only in the binding of NK cells to endothelial cells, but also in NK cell-mediated endothelium damage, which may result in vascular injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754298     DOI: 10.4049/jimmunol.164.8.4055

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.

Authors:  P Fraticelli; M Sironi; G Bianchi; D D'Ambrosio; C Albanesi; A Stoppacciaro; M Chieppa; P Allavena; L Ruco; G Girolomoni; F Sinigaglia; A Vecchi; A Mantovani
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Human cytomegalovirus-specific CD4+-T-cell cytokine response induces fractalkine in endothelial cells.

Authors:  Cynthia A Bolovan-Fritts; Rodney N Trout; Stephen A Spector
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

3.  Neuron-Microglia Dialogue and Hippocampal Neurogenesis in the Aged Brain.

Authors:  Carmelina Gemma; Adam D Bachstetter; Paula C Bickford
Journal:  Aging Dis       Date:  2010-12-01       Impact factor: 6.745

Review 4.  Therapeutic potential of fractalkine: a novel approach to metastatic colon cancer.

Authors:  M Brueckmann; M Borggrefe
Journal:  Gut       Date:  2007-03       Impact factor: 23.059

5.  High T-cell response to human cytomegalovirus induces chemokine-mediated endothelial cell damage.

Authors:  Cynthia A Bolovan-Fritts; Rodney N Trout; Stephen A Spector
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

Review 6.  Fractalkine/CX3CL1: a potential new target for inflammatory diseases.

Authors:  Brian A Jones; Maria Beamer; Salahuddin Ahmed
Journal:  Mol Interv       Date:  2010-10

7.  Matrix metalloproteinase-1 produced by human CXCL12-stimulated natural killer cells.

Authors:  Seiji Goda; Hiroshi Inoue; Hisanori Umehara; Michihiko Miyaji; Yutaka Nagano; Nari Harakawa; Hisao Imai; Peter Lee; James B Macarthy; Takashi Ikeo; Naochika Domae; Yoji Shimizu; Joji Iida
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

8.  Expression of CX3CL1 (fractalkine) in mice with endothelial-target rickettsial infection of the spotted-fever group.

Authors:  Gustavo Valbuena; David H Walker
Journal:  Virchows Arch       Date:  2004-10-05       Impact factor: 4.064

9.  Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Authors:  Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

10.  Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Authors:  Timothy Kottke; Rosa M Diaz; Karen Kaluza; Jose Pulido; Feorillo Galivo; Phonphimon Wongthida; Jill Thompson; Candice Willmon; Glen N Barber; John Chester; Peter Selby; Scott Strome; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.